Shyamakant Giri has been appointed Group Chief Executive Officer of Apothecon Pharmaceuticals Pvt. Ltd., a key leadership position that marks a strategic milestone for the company as it embarks on its next phase of growth and international expansion. Effective May 11, 2026, Giri will be responsible for steering the organisation’s overall direction, overseeing business operations, and driving growth initiatives across key markets.
A seasoned leader in the pharmaceutical and healthcare sector, Giri brings over two decades of broad-based experience spanning global operations, diagnostics, biologics, hospital services, and international market development. His appointment reflects Apothecon’s focus on strengthening executive leadership as it scales its presence both in India and abroad.
Prior to joining Apothecon Group, Giri served as Chief Executive Officer at Gland Pharma Limited, where he was responsible for one of India’s leading injectables and specialty drug manufacturers. In this role, he oversaw a $650 million profit and loss portfolio, directed 11 manufacturing facilities, and guided more than 5,000 employees — all while building strategies to accelerate the company’s growth in injectable and biologics CDMO (Contract Development and Manufacturing Organisation).
Before his tenure at Gland Pharma, Giri held top leadership roles at Amneal Pharmaceuticals, where he served as Managing Director and President of India and Rest of World Markets. There, he played a pivotal role in expanding commercial footprints and enhancing regional market penetration. His experience also includes senior executive positions at leading healthcare and pharmaceutical organisations such as Abbott, Rivaara Labs, and Wockhardt Ltd., reinforcing his expertise in scaling businesses and managing diverse healthcare portfolios.
Throughout his career, Mr. Giri has been recognised for his leadership in business transformation, diagnostics, global commercial strategy, and strategic expansion across multiple regions including India, Africa, the Commonwealth of Independent States (CIS), Latin America (LATAM), the Gulf Cooperation Council (GCC) markets, and Southeast Asia. His extensive background positions him well to lead Apothecon’s strategic initiatives in both regulated and emerging markets.
The appointment comes at a time when Apothecon Group is scaling its capabilities, with operations spanning India and the United States through its subsidiaries. With Giri at the helm, the company aims to accelerate growth, strengthen global operations, and reinforce its competitive position in the speciality pharmaceuticals landscape.
